Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling

Hypoxia contributes to resistance of tumors to some cytotoxic drugs and to radiotherapy, but can in principle be exploited with hypoxia-activated prodrugs (HAP). HAP in clinical development fall into two broad groups. Class I HAP (like the benzotriazine N-oxides tirapazamine and SN30000), are activa...

Descripción completa

Detalles Bibliográficos
Autores principales: Foehrenbacher, Annika, Secomb, Timothy W., Wilson, William R., Hicks, Kevin O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873531/
https://www.ncbi.nlm.nih.gov/pubmed/24409417
http://dx.doi.org/10.3389/fonc.2013.00314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873531/
https://www.ncbi.nlm.nih.gov/pubmed/24409417
http://dx.doi.org/10.3389/fonc.2013.00314

Ejemplares similares